Home high-cost drugs

Keyword: high-cost drugs

35 results found

Many Canadians living with asthma are experiencing poor control over their symptoms, impacting the workplace, said Anjila Arora, director of pharmaceutical benefits at Sun Life Financial Inc., during Benefits Canada’s 2023 Face to Face Drug Plan Management Forum. Between 53 and 90 per cent of asthmatic Canadians meet at least one criteria for poor control […]

It’s important for private payers and employers to be nimble and innovative to support plan members seeking access to novel drugs and treatments by addressing common hurdles within their own drug plans, said John Adams, chair of the board of directors for patient advocacy group Best Medicines Coalition, during a session at Benefits Canada’s 2023 Face […]

A story on mental-health themes and challenges for 2024 was the most-read story on BenefitsCanada.com this week. Here are the top five human resources, benefits, pension and investment stories of the past week: 1. Expert panel: Employers taking preventative, holistic approach to employee mental health in 2024 2. AI holds uncapped potential for pension plan sponsors’ administration, communications: […]

  • By: Staff
  • January 12, 2024 January 11, 2024
  • 09:00

The 10 highest-cost drugs reimbursed by public drug plans in Canada in the 2021/22 fiscal year were all rare disease treatments with annual treatment costs of more than $250,000, according to a new report by the Patented Medicine Prices Review Board. It found the increased use of high-cost drugs continued to be the main factor […]


More than half (58 per cent) of global insurers say they anticipate higher health benefits costs over the next three years, with the average global cost trend projected to increase by 9.9 per cent in 2024, according to a new survey by WTW. The survey, which polled more than 260 insurers representing 66 countries, found […]

  • By: Staff
  • December 6, 2023 December 5, 2023
  • 09:00

The federal government is appointing members to an implementation advisory group to support the launch of its national strategy for drugs for rare diseases. The members from Canada’s private payer community include: Stephen Frank, president and chief executive officer of the Canadian Life and Health Insurance Association; Joanne Jung, Canadian pharmacy and clinical practice leader at […]

  • By: Staff
  • November 3, 2023 November 7, 2023
  • 09:00

Three-fifths (60 per cent) of benefits plan sponsors say the costs of their health benefits plan increased in the past three years, according to the 2023 Benefits Canada Healthcare Survey. It found this percentage decreased from 66 per cent when the question was last asked in 2016 and was unchanged from 2015 (60 per cent). […]

  • By: Staff
  • September 25, 2023 September 22, 2023
  • 09:00

A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug plan costs but promising pharmaceutical innovation, says Joe Farago, executive director of private payers and investment at Innovative Medicines Canada. The report also found the number of new medicines launched in Canada was higher than the median for Organisation for […]

  • By: Sadie Janes
  • September 20, 2023 September 20, 2023
  • 09:00

More than three-quarters (77 per cent) of large U.S. employers are reporting an increase in mental-health needs among their workforces, according to a new survey by Business Group on Health. The survey, which polled around 150 large employers employing 19 million people, found this is a 33 per cent increase compared to last year, when […]

  • By: Staff
  • August 22, 2023 August 22, 2023
  • 15:00

Canadian plan sponsors and insurers are revisiting how they classify obesity drugs under their benefits plans, amid plan members’ rising demand for Ozempic as a weight-loss treatment. Ozempic, also known under the generic name semaglutide, is a drug used to treat type 2 diabetes. However, the medication has also been credited as a weight-loss treatment, […]